-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| Sector | |
| Industry | |
| ISIN | US78397T1117 |
| PE Ratio | 0.09 |
|---|---|
| Beta | 0.61 |
| Market Cap | None |
| Target Price | None |
| Dividend Yield | None |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SABSW using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026